Antiviral resistance in influenza viruses circulating in Central and South America based on the detection of established genetic markers

Influenza and other Respiratory Viruses

Volumn 3, Issue 2, 2009, Pages 69-74

  García, Josefina ^a   Sovero, Merly ^a   Torres, Alberto L ^a   Gomez, Jorge ^b   Douce, Richard ^c   Barrantes, Melvin ^d   Sanchez, Felix ^e   Jimenez, Mirna ^f   Comach, Guillermo ^g   De Rivera, Ivette ^h   Agudo, Roberto ⁱ   Kochel, Tadeusz ^a  

^a California   (Peru)

^b Perú   (Peru)

^c HOSPITAL VOZANDES   (Ecuador)

^d Hospital Solano   (Argentina)

^e Hospital Infantil Manuel de Jesus Rivera   (Nicaragua)

^f Hospital Nacional del Metapan   (El Salvador)

^g LARDIDEV Biomed UC   (Venezuela)

^h NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

ⁱ Ministerio de Salud Y Prevision Social   (Bolivia)

Author keywords

Adamantanes; Amantadine; Influenza; Neuraminidase Inhibitors; Oseltamivir; Resistance

Indexed keywords

ADAMANTANE DERIVATIVE; AMANTADINE; HEMAGGLUTININ; MATRIX PROTEIN; OSELTAMIVIR; PROTEIN M1; PROTEIN M2; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG;

ANTIBIOTIC SENSITIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE IDENTIFICATION; GENE SEQUENCE; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MARKER GENE; NONHUMAN; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; SPECIES COMPARISON; SPECIES DIFFERENCE; VIRUS DETECTION; VIRUS ISOLATION; VIRUS STRAIN; VIRUS SURVIVAL; VIRUS VIRULENCE;

EID: 62149124725     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2009.00072.x     Document Type: Article

References (28)

1. Turner D, Wailoo A, Nicholson K, Cooper N, Sutton A, Abrams K. Systematic review and economic decision modelling for the prevention and treatment of influenza A and B. Health Technol Assess 2003; 7:1-170. iii-iv, xi-xiii
2. Englund JA. Antiviral therapy of influenza. Semin Pediatr Infect Dis 2002; 13:120-128.
3. Fouchier RA, Munster V, Wallensten A et al. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 2005; 79:2814-2822.
4. Nicholson KG, Wood JM, Zambon M. Influenza. Lancet 2003; 362:1733-1745.
5. Boivin G, Goyette N, Bernatchez H. Prolonged excretion of amantadine-resistant influenza a virus quasi species after cessation of antiviral therapy in an immunocompromised patient. Clin Infect Dis 2002; 34:E23-E25.
6. Hay AJ, Zambon MC, Wolstenholme AJ, Skehel JJ, Smith MH. Molecular basis of resistance of influenza A viruses to amantadine. J Antimicrob Chemother 1986; 18(Suppl. B):19-29.
7. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 2006; 295:891-894.
8. Bright RA, Medina MJ, Xu X et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: A cause for concern. Lancet 2005; 366:1175-1181.
9. Ziegler T, Hemphill ML, Ziegler ML et al. Low incidence of rimantadine resistance in field isolates of influenza A viruses. J Infect Dis 1999; 180:935-939.
10. Deyde VM, Xu X, Bright RA et al. Surveillance of resistance to adamantanes among influenza A(H3N2) and A(H1N1) viruses isolated worldwide. J Infect Dis 2007; 196:249-257.
11. Hayden F, Klimov A, Tashiro M et al. Neuraminidase inhibitor susceptibility network position statement: Antiviral resistance in influenza A/H5N1 viruses. Antivir Ther 2005; 10:873-877.
12. Carr MJ, Sayre N, Duffy M, Connell J, Hall WW. Rapid molecular detection of the H275Y oseltamivir resistance gene mutation in circulating influenza A (H1N1) viruses. J Virol Methods 2008; 153:257-262.
13. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther 2007; 12:603-616.
14. Oshitani H, Kamigaki T, Suzuki A. Major issues and chalenges of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2008; 14:875-880. [Epub ahead of print]
15. Mishin VP, Hayden FG, Gubareva LV. Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors. Antimicrob Agents Chemother 2005; 49:4515-4520.
16. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402.
17. Saito R, Li D, Suzuki Y et al. High prevalence of amantadine-resistance influenza a (H3N2) in six prefectures, Japan, in the 2005-2006 season. J Med Virol 2007; 79:1569-1576.
18. World Health Organization. WHO/ECDC frequently asked questions for oseltamivir resistance. Available at: (http://www.who.int/csr/disease/ influenza/oseltamivir_faqs/en/), [accessed on 04 February 2008].
19. Enserink M. Oseltamivir becomes plentiful-but still not cheap. Science 2006; 312:382-383.
20. Ministerio de Salud del Peru. Plan nacional de preparación y respuesta frente a una potencial pandemia de influenza. Perú: Gobierno, 2005 http://www.epi.minsal.cl/webInfluenza/enelmundo/ Plan_Influenza_Peru.pdf.
21. Saito R, Oshitani H, Masuda H, Suzuki H. Detection of amantadine-resistant influenza A virus strains in nursing homes by PCR-restriction fragment length polymorphism analysis with nasopharyngeal swabs. J Clin Microbiol 2002; 40:84-88.
22. Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian influenza viruses isolated in North America and Asia. Virol 2005; 341:102-106.
23. Barr IG, Komadina N, Durrant C, Sjogren H, Hurt AC, Shaw RP. Circulation and antigenic drift in human influenza B viruses in SE Asia and Oceania since 2000. Commun Dis Intell 2006; 30:350-357.
24. Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 2007; 24:1811-1820.
25. Lackenby A, Hungnes O, Dudman SG et al. Emergence of resistance to oseltamivir among influenza A(H1N1) viruses in Europe. Euro Surveill 2008; 13:8026.
26. Rimmelzwaan GF, de Jong JC, Donker GA, Meijer A, Fouchier RA, Osterhaus AD. Influenza season 2007/'08 in the Netherlands: Antigenic variation, oseltamivir resistance and vaccine composition for the 2008/'09 season. Ned Tijdschr Geneeskd 2008; 152:2138-2144.
27. European Center for Disease Prevention and Control. Antivirals and antiviral resistance-influenza. Resistance to Oseltamivir (tamiflu) found in some European influenza virus samples. Available at: (http://ecdc.europa.eu/Health_topics/influenza/antivirals.html), [accessed on 21 February 2008].
28. Mounier-Jack S, Coker RJ. How prepared is Europe for pandemic influenza? Analysis of national plans Lancet 2006; 367:1405-1411.